SLC5A2 and hydrops fetalis: The sodium-glucose cotransporter-2 inhibitors (SGLT2i) have been established as an important component in the management of HFrEF; however, they have a weaker (class 2a) recommendation in the 2022 American College of Cardiology (ACC)/American Heart Association (AHA) guidelines for HFmrEF and HFpEF (7) although in the most recent update of the European guidelines they have gotten a class Ia recommendation for reducing the risk of HF hospitalization or cardiovascular death (8).